Arcturus Therapeutics Holdings annual operating margin
2018
2019
2020
2021
2022
2023
2024
2025
Arcturus Therapeutics Holdings's operating margin was −92.96% for fiscal 2025.
View full Arcturus Therapeutics Holdings company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −92.96% | −30.15 pp |
| 2024 | 2024-12-31 | −62.81% | −15.93 pp |
| 2023 | 2023-12-31 | −46.89% | −52.80 pp |
| 2022 | 2022-12-31 | 5.91% | +1647.24 pp |
| 2021 | 2021-12-31 | −1,641.33% | −891.52 pp |
| 2020 | 2020-12-31 | −749.81% | −627.08 pp |
| 2019 | 2019-12-31 | −122.72% | +15.73 pp |
| 2018 | 2018-12-31 | −138.46% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −863.30% | −822.25 pp |
| Q1 2026 | 2026-03-31 | −1,403.74% | −1346.47 pp |
| Q4 2025 | 2025-12-31 | −434.99% | −288.30 pp |
| Q3 2025 | 2025-09-30 | −96.27% | −70.51 pp |
| Q2 2025 | 2025-06-30 | −41.04% | +1.33 pp |
| Q1 2025 | 2025-03-31 | −57.27% | +22.74 pp |
| Q4 2024 | 2024-12-31 | −146.68% | −87.46 pp |
| Q3 2024 | 2024-09-30 | −25.76% | +17.02 pp |
| Q2 2024 | 2024-06-30 | −42.37% | +484.05 pp |
| Q1 2024 | 2024-03-31 | −80.01% | −98.38 pp |
| Q4 2023 | 2023-12-31 | −59.22% | −134.99 pp |
| Q3 2023 | 2023-09-30 | −42.79% | +232.53 pp |
| Q2 2023 | 2023-06-30 | −526.42% | −444.89 pp |
| Q1 2023 | 2023-03-31 | 18.38% | +979.08 pp |
| Q4 2022 | 2022-12-31 | 75.77% | +725.49 pp |
| Q3 2022 | 2022-09-30 | −275.32% | +1933.18 pp |
| Q2 2022 | 2022-06-30 | −81.53% | +2603.13 pp |
| Q1 2022 | 2022-03-31 | −960.70% | +1750.44 pp |
| Q4 2021 | 2021-12-31 | −649.72% | +739.11 pp |
| Q3 2021 | 2021-09-30 | −2,208.49% | −1311.02 pp |
| Q2 2021 | 2021-06-30 | −2,684.66% | −2252.19 pp |
| Q1 2021 | 2021-03-31 | −2,711.14% | −2353.55 pp |
| Q4 2020 | 2020-12-31 | −1,388.83% | −1024.38 pp |
| Q3 2020 | 2020-09-30 | −897.47% | −667.94 pp |
| Q2 2020 | 2020-06-30 | −432.47% | −426.84 pp |
| Q1 2020 | 2020-03-31 | −357.60% | −207.99 pp |
| Q4 2019 | 2019-12-31 | −364.45% | −237.20 pp |
| Q3 2019 | 2019-09-30 | −229.54% | +192.59 pp |
| Q2 2019 | 2019-06-30 | −5.63% | — |
| Q1 2019 | 2019-03-31 | −149.61% | — |
| Q3 2018 | 2018-09-30 | −127.26% | — |
| Q2 2018 | 2018-06-30 | −422.13% | — |
Over the last five reported fiscal years, Arcturus Therapeutics Holdings's operating margin increased from −749.81% to −92.96%, a change of +656.84 percentage points. The latest reported quarter, Q2 2026, shows −863.30%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcturus Therapeutics Holdings filings at SEC.gov ↗